243 results on '"Casato, Milvia"'
Search Results
2. COVID-19 and Mixed Cryoglobulinemia Syndrome: Long-Term Survey Study on the Prevalence and Outcome, Vaccine Safety, and Immunogenicity
3. Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC)
4. Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature
5. Correction to: Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC)
6. Surface antigen serocleared hepatitis B virus infection increases the risk of mixed cryoglobulinemia vasculitis in male patients with chronic hepatitis C.
7. Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar)
8. A stereotyped light chain may shape virus-specific B-cell receptors in HCV-dependent lymphoproliferative disorders
9. Dual stimulation by autoantigen and CpG fosters the proliferation of exhausted rheumatoid factor-specific CD21low B cells in hepatitis C virus-cured mixed cryoglobulinemia.
10. Persistence of monoclonal B‐cell expansion and intraclonal diversification despite virus eradication in patients affected by hepatitis C virus‐associated lymphoproliferative disorders.
11. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection
12. Opposite Effects of mRNA-Based and Adenovirus-Vectored SARS-CoV-2 Vaccines on Regulatory T Cells: A Pilot Study
13. Dual stimulation by autoantigen and CpG fosters the proliferation of exhausted rheumatoid factor-specific CD21low B cells in hepatitis C virus-cured mixed cryoglobulinemia
14. Correction to: Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC)
15. Efficacy and safety of long-term treatment with low-dose rituximab for relapsing mixed cryoglobulinemia vasculitis
16. Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC)
17. Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases
18. Relapse of HCV-Cryoglobulinemic Vasculitis Following Sustained Viral Response after Interferon-free Direct-Acting Antivirals
19. COVID-19 vaccination rate and safety profile in a multicentre Italian population affected by mixed cryoglobulinaemic vasculitis
20. Relapse of Hepatitis C Virus Cryoglobulinemic Vasculitis After Sustained Viral Response After Interferon-Free Direct-Acting Antivirals
21. COVID-19 vaccine immunogenicity in 16 patients with autoimmune systemic diseases. Lack of both humoral and cellular response to booster dose and ongoing disease modifying therapies
22. Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups
23. Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2
24. The case for cost-effectively treating cryoglobulinemic vasculitis with interferon-free anti–hepatitis C virus therapy
25. CD21low B cells are predictive markers of new digital ulcers in systemic sclerosis
26. Provisional recommendations for SARS-CoV-2 vaccination in patients with cryoglobulinaemic vasculitis
27. Cryoglobulins: putative effectors of adaptive immune response
28. Mutational and immunogenetic landscape of HCV ‐associated B‐cell lymphoproliferative disorders
29. Persistence of a Large Population of Exhausted Monoclonal B cells in Mixed Cryoglobuliemia After the Eradication of Hepatitis C Virus Infection
30. Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression
31. Clinico‐immunological outcomes of HCV‐cured cryoglobulinemia: Lower relapse rate with interferon‐based than interferon‐free therapy
32. Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2.
33. Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar)
34. HCV infection in a patient with hyper-IgM syndrome
35. CD21low B cells are predictive markers of new digital ulcers in systemic sclerosis.
36. Cl− regulates cryoglobulin structure: a new hypothesis for the physiopathological mechanism of temperature non-dependent cryoprecipitation
37. Analysis of the Dynamics of Cryoaggregation by Light-Scattering Spectrometry1)
38. Regression of Splenic Lymphoma after Treatment of Hepatitis C Virus Infection
39. Hepatitis C virus and nephrotic syndrome
40. MIXED CRYOGLOBULINEMIA SECONDARY TO VISCERAL LEISHMANIASIS
41. Long‐lasting persistence of large B‐cell clones in hepatitis C virus‐cured patients with complete response of mixed cryoglobulinaemia vasculitis
42. Persistence of Pathogenic B-Cell Clones and Relapse of Cryoglobulinemic Vasculitis in HCV-Cured Patients
43. Interferon for Hepatitis C Virus-Negative Type II Mixed Cryoglobulinemia
44. Interferon-α treatment of hepatitis C virus-associated mixed cryoglobulinemia
45. Influence of age and autoimmunity on liver disease in HCV-associated type II mixed cryoglobulinemia
46. Reversion of anergy signatures in clonal CD21low B cells of mixed cryoglobulinemia after clearance of HCV viremia
47. Clinico‐immunological outcomes of HCV‐cured cryoglobulinemia: Lower relapse rate with interferon‐based than interferon‐free therapy.
48. Granulocytopenia after combined therapy with interferon and angiotensin-converting enzyme inhibitor: evidence for a synergistic hematologic toxicity
49. HBV messing with the B-cell genome leads to DLBCL
50. Late relapses of hepatitis C virus-cured mixed cryoglobulinaemia associated with infection or cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.